Literature DB >> 16168725

Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.

S Danese1, S Semeraro, M Marini, I Roberto, A Armuzzi, A Papa, A Gasbarrini.   

Abstract

Mucosal endothelium has become one of the major areas of investigation in gut inflammation. It is now well recognised that it plays an active role in the pathogenesis of both forms of inflammatory bowel disease, Crohn's disease and ulcerative colitis, since endothelial cells regulate mucosal immune homeostasis, acting as "gatekeepers", controlling leukocyte accumulation in the interstitial compartment. This process is mediated by leukocyte-endothelial adhesion molecules. This paper reviews the major molecules that mediate leukocyte-endothelial interactions, and summarises the results of the most recent clinical trials targeting adhesion molecules in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168725     DOI: 10.1016/j.dld.2005.03.013

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  19 in total

Review 1.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

2.  Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-κB and JNK activation in intestinal epithelial cells.

Authors:  Young-A Song; Young-Lan Park; Sun-Hye Yoon; Kyu-Yeol Kim; Sung-Bum Cho; Wan-Sik Lee; Ik-Joo Chung; Young-Eun Joo
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

Review 3.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 4.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

5.  Alemtuzumab and natalizumab: the monoclonal antibody story continues.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

Review 6.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.

Authors:  Brijen Shah; Lloyd Mayer
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

7.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

8.  Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent.

Authors:  Claire Billerey-Larmonier; Jennifer K Uno; Nicolas Larmonier; Anna J Midura; Barbara Timmermann; Fayez K Ghishan; Pawel R Kiela
Journal:  Inflamm Bowel Dis       Date:  2008-06       Impact factor: 5.325

9.  Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis.

Authors:  Takushi Namba; Ken-Ichiro Tanaka; Yosuke Ito; Tomoaki Ishihara; Tatsuya Hoshino; Tomomi Gotoh; Motoyoshi Endo; Keizo Sato; Tohru Mizushima
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

Review 10.  The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.

Authors:  Gionata Fiorino; Daniela Gilardi; Silvio Danese
Journal:  Therap Adv Gastroenterol       Date:  2016-05-19       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.